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Abstract
Following a report of the efficacy of total lymphoid irradiation (TLI) in the treatment of chronic progressive multiple sclerosis a further randomnsed doubleblind placebo-controlled study was undertaken with the intention of entering 56 patients. In the event it was possible to recruit only 27 patients in a 2 5 year period. Three patients received active treatment openly and 24 were randomised to either active (14) or sham (10) treatment. Treatment was 1980 cGy to the lymphoid system and spleen or sham treatment after full simulation. The primary outcome measure was a comparison of the mean rates of change between treatment groups on the expanded Kurtzke disability scale (EDSS) over the two year follow up period. Patients were also assessed on other clinical outcome measures, psychometry, and serial MRI of the brain. Active treatment resulted in a profound and prolonged fall in T lymphocytes especially those with the CD4 marker and a reversal in CD4:CD8 ratio. No significant benefit was demonstrated on the rate of clinical disease progression (EDSS). A small but significant benefit was found on Multiple sclerosis is. an inflammatory disease of the CNS in which there is episodic impairment of the blood brain barrier, perivascular inflammation, and demyelination: it is thought that immunoregulatory defects, especially in T cell function, play an important part in pathogenesis.'-" In recent years there have been several controlled and blinded trials of therapy that have attempted to modulate or suppress immune mechanisms to alter the clinical course of multiple sclerosissl1 with modest or no benefits and, often, clinically relevant side effects. The high sensitivity of lymphocyte populations to ionising radiation" has led to the use of total lymphoid irradiation (TLI) in some non-malignant diseases thought to have an immune basis. These include rheumatoid arthritis'2-'5 and lupus nephritis.'6 TLI has also been used in preparatory treatment for organ transplantation. '7 There is evidence of potent and prolonged effects of TLI on circulating populations of lymphocytes and some evidence of clinical efficacy. Preliminary'8 and later definitive'9 results in chronic progressive multiple sclerosis showed some benefit from TLI (1980 cGy) compared with sham treatment in a double-blind study on 40 (EDSS) in the preceding year, to score at <6-5 on the scale at the time of recruitment, to be able to attend St Thomas' Hospital and the National Hospital regularly, and to give informed consent. Exclusion criteria were severe psychiatric disorder or cognitive impairment sufficient to preclude informed consent, evidence of chronic infection, lung disease, other serious medical disorder or previous neoplasm, leucopenia <4.5 x 109/1, platelet count <100 x 109 or anaemia, previous immunosuppressive medication (other than corticosteroids), pregnancy or the desire (by either partner) for future pregnancy, and inadequate social support at home. Patients were provided with an information sheet about the trial. After clinical assessment the trial was discussed in detail normally together with a close relative or carer: special attention was paid to counselling those female patients who were premenopausal about the likelihood of amenorrhoea. Written consent for the study was obtained at a subsequent separate visit to the clinic or an admission before the start of the trial. The trial received ethical approval from the West Lambeth Health Authority Ethics Committee.
PATIENT NUMBER It was our intention to randomise 56 patients to this study: this was based on detecting a mean difference between the treated and control groups of 0 7 (SD 1.34) points on the EDSS4 over a year (a 0-05, power 0-8). In the event enough suitable patients could not be recruited in a reasonable time. Over a two year period 66 patients were referred as fulfilling the trial criteria of whom 15 were unsuitable for various reasons (age, lack of documented progression, concomitant or previous general medical disorder) and 24 otherwise suitable patients declined entry after information and counselling. Three patients were not randomised and were treated with TLI openly but had assessments performed blind: they included the first two patients with multiple sclerosis treated with TLI by us and one patient who had agreed to trial entry but subsequently became incompetent to give consent due to severe and rapidly progressive multiple sclerosis and was given active treatment. Twenty four patients were randomly allocated to treatment with TLI or sham treatment.
TREATMENT TECHNIQUE Lung function (vital capacity and peak flow rate), chest radiograph, electrocardiogram, abdominal ultrasound to localise kidneys and spleen, serum biochemistry, thyroid function test, and full blood count were undertaken before radiotherapy planning. Treatment for all patients was planned on a simulator in the prone and supine position with hands on hips. The modified mantle field extended from the top of the thyroid cartilage to the lower border of the first lumbar vertebra to include the spleen as localised by ultrasound. The inverted Y field extended from the middle of the second lumbar vertebra to the lower border of the obturator foramina with central pelvic shielding. to ensure consistency of the imaging plane throughout the study. In previous studies," repositioning has been shown to be better than ±40: this has been improved further by the current method, thus facilitating comparison between serial images.'2 All images were viewed and scored by an experienced neuroradiologist (IFM) who was unaware of the patients' treatment. To calculate the total lesion load on the baseline MRI, the brain was divided into 15 anatomical regions and the number and size of each lesion was recorded. Lesion size was scored as: <5 mm in the largest diameter 1 point; 5-10 mm 2 points; >10 mm 3 points. An extra point was scored if a lesion displayed confluence. At follow up studies (six, 12, 18, and 24 months) changes from the previous images were recorded as: new lesions, enlarging lesions, lesions showing a reduction in size, and lesions that had disappeared altogether. In the analysis new and enlarged lesions were summed as were lesions that became smaller or disappeared. Gadolinium DTPA was not systematically used as a contrast agent in this study as it was not generally available when the study began but it was administered on at least one occasion to 13 patients.
Blood and lymphocyte subset counts Routine blood counts during and after treatment were undertaken on a Coulter counter. Venous blood samples were taken before treatment, on days 9 and 19 of treatment, and at intervals of three months afterwards for up to two years. Mononuclear cells were isolated from whole blood by buoyant density centrifugation. Cells were labelled with a range of directly conjugated monoclonal antibodies (Becton-Dickinson Ltd) and the proportion of fluorescent cells was measured by flow cytometry (FACScan, Becton Dickinson Ltd). Absolute numbers of fluorescent lymphocytes were determined from the haematological lymphocyte count.
Results Twenty-seven patients were entered into the study, three of whom were treated openly but had blinded assessments of their MRI images and physical state. Of the remainder, 14 were randomised to TLI and 10 to sham TLI. Table 1 shows the clinical details together with the initial lesion load on MRI.
Differences between the treatment groups for sex distribution, disability, or lesion load on MRI scan were small. The sham treated group had had multiple sclerosis for slightly longer, and had fewer patients with primary progressive disease (1/10 compared with 5/17 in active group). This potentially important factor of different numbers of such patients is taken into account in the analysis. Patients treated with TLI had on average received a course of steroids more recently than the sham group.
All patients had a full course of TLI or sham treatment apart from one who devel- 18 24 systems scales there seemed to be a small but Time (months) significant difference in the rate of decline of the score for bladder dysfunction that r out of 17 had a decline in haemoglobin favoured the treated group (all p = 004, ranicentration >2 g/dl, and two out of 17 domised only p = 0-02). There was a similar ients had platelet counts <100 x 109/l but non-significant trend in the visual funcring the treatment phase. These indices tion subscale again favouring the treated I returned to normal in all but one patient group (all p = 0 07, randomised only p = the two month follow up.
0-06). One sham treated patient died of mulr cells, particularly those expressing CD4, tiple sclerosis before the six month follow up re profoundly depressed during and after and those scales that did not score death were atment with TLI with gradual but incom-subsequently set to their maximum "worst" te recovery over the two year follow up score; removing these scores did not materi-.iod. By contrast there was a rapid partial ally influence the results. recovery in CD8 cells in the three months after completion of therapy. Incomplete recovery of CD4 T cells resulted in a reversal of the CD4:CD8 ratio (fig 2) , which lasted from three months to the end of follow up. B cell numbers were initially depressed by therapy but had recovered by three month follow up. 
MRI RESULTS
These results include all studies undertaken in treatment and sham groups before and at six, 12, 18, and 24 months after treatment. Two patients in the sham group did not have 12 month studies (one death and one unable to attend) but one was imaged at six months. Two treated patients could not attend at six months but had imaging at 12 months. Table   3 shows the mean (SE) numbers of new or enlarged lesions, those that were decreased or gone and the net change in lesion count for successive six month follow up periods. baseline and at six, 12, 18 and 24 months were used to construct lesion scores at each time point (fig 4) . On the relatively undemanding assumption that variation about the trend at one point is independent of that at other points the individual sequences can then be modelled and compared. This approach was used to assess the effect of treatment by testing whether there was any systematic difference in the pattern of change over time between the two treatment groups. The trends over time in the lesion scores were analysed by assuming that the counts at any point came from a normal distribution and fitting trends to each patient. The trends were constrained to follow the same average pattern within each treatment group while allowing the pattern to vary between treatment groups. A plot of the residuals from the non-linear trend model showed that, although there was some evidence of skewness, the underlying variation was adequately nornal. With or without the three patients who were not randomly allocated to treatment it was clear that straight line models were adequate to represent trends in the data. The gradients (lesion score/time) of the placebo and treatment groups were significantly (p < 0O01) different. Lesion scores in the sham treated group tended to increase compared with those in the treated group, which tended to decrease. No effect of the initial disease pattern (relapsing. progressive or primary progressive) was seen (p = 0 39).
PSYCHOMETRIC ASSESSMENTS
Complete two year follow up data sets were obtained for only 11 treated and five sham treated patients. There were no significant differences over time in the changes between the two treatment groups with respect to the WAIS verbal subtests, the speed tests, Raven's matrices, and verbal and visual recognition memory tests. On the Wisconsin card sorting test (table 5) two of the three performance measures showed a significant difference that favoured the sham treated group, who seemed to show some improvement over the follow up period. with continuity correction 7-2 and 6-0 respectively, p < 0 02). There was a significant excess of patients noticing body hair loss in the treated group (X2 test 1 1 51, p < 0 00 1).
Discussion
In this study we have treated a highly selected small group of patients with chronic progressive disability due to multiple sclerosis from a large local population of patients with multiple sclerosis (about 7000 in the Greater London area). The patients had significant disability that had substantially worsened in the year before trial entry as measured on the Kurtzke scale. Although it has recently been noted that there may be differences in MRI appearances of primary progressive multiple sclerosis and secondary progressive disease33 we found no difference in mean lesion load between these two groups in this small prospectively classified study group before treatment (table 7) . Nevertheless the imbalance in the make up of the two treatment groups for disease type has been allowed for in the analysis of clinical data. There was no correlation between lesion load and pretreatment expanded Kurtzke disability status score (r2 = 0.08). The treatment protocol used was similar to that used in the United States trial.'934 It followed the same modified regimen and treatment was administered over a similar total period (United Kingdom study mean 37, United States 39 days): the calculated spinal cord dose was a little higher at 1265 cGy in our study compared to 1050 cGy in the United States. In the current study the absolute lymphocyte count had fallen by 83% of the pretreatment value at the end of treatment and by 63% one month later, the last figure comparing with a 73% decline noted previously." At one year after treatment 94% of patients (all but one) had lymphocyte counts below the pretreatment values and 41% had counts = < 900/mm3 compared with figures of 75% and 50% respectively in the United States study. The pattern and degree of change of CD4+ and CD8+ lymphocytes and the CD4+: CD8+ ratio were similar in the two studies. We would thus judge that TLI had had a generally similar biological effect. It has been noted in patients with rheumatoid disease that similar radiological effects on the lymphocyte count may be obtained by 2000 cGy excluding the spleen. '5 Our patients were on average six years younger in the treated group and 4-7 years younger in the sham group, but of similar sex distribution to those in the United States study. Although the standard EDSS was not used in the United States study their disability scale had some similar features and it is likely that our patients were slightly less disabled than theirs at entry: this is reinforced by their average functional scale scores at entry of 5-9 and 5-6 (treated and sham) compared with our entry scores on this scale of 5 0 and 4-0 (treated and sham). It is not possible to judge from the United States study to what extent patients had declined in disability in the year before entry.
Although patients who developed amenorrhoea or hair loss often guessed correctly that they had received active treatment when asked at six months five of nine sham treated patients alive thought that they had also received active treatment. It was thus only partially the case that patients were blind to the treatment which they had received. The clinical assessor and psychologist examined and tested the patients clothed, however, and did not discuss treatment or side effects. The MRI scans were assessed by a radiologist (IFM) who was not involved in the technical execution of the scans and who did not have access to either clinical details or treatment codes.
Treated patients had fewer new or enlarged MRI brain lesions with more being smaller or disappearing than the sham treated group based on a trend analysis over the whole follow up period. The mean rates of change in lesion score were significantly different in the treated and control group indi-cating that overall there had been a net loss of lesions in the treated group and a slight gain in the sham group. Allowing for disease pattern did not affect the results. It is clear, however, that lesion activity as reflected by unenhanced MRI was only partially suppressed by treatment as 14 out of 17 treated patients developed at least some new or enlarging lesions during follow up. It is possible that the greater number of lesions disappearing or getting smaller in the treated group, particularly during the first six months, was due to there having been more active lesions in that group on the baseline images. This possibility cannot be excluded without having had either more than one pretreatment study or having a gadolinium enhanced study in all patients. More frequent MRI in the first year of the study, particularly if combined with gadolinium enhancement,35 might have also allowed the recognition of turnover of a greater number of lesions and thereby increased the sensitivity of the technique for determining a treatment effect. Furthermore, we did not undertake routine imaging of the spinal cord: this was, at the time, difficult to quantify technically and in this study the cord, unlike the brain, received a significant radiation dose that may have had a direct effect on lesion size and intensity.
Despite the slight radiological benefit, we found little evidence of clinical benefit from TLI as indicated by the mean rates of progression of disability or other clinical indices. In the United States trial benefit was evident on the functional scale but less obvious on the disability scale used. We found that there was a close correlation between the expanded Kurtzke disability status score and the functional scale at any particular time point (for example, Spearman coefficient 095, 95% CI 0 90 to 098 for pretreatment scores and 0-87, 95% CI 0-74 to 0-94 at six months after treatment). On neither scale, however, was there any indication of a significant benefit from treatment whether or not the three nonrandomised patients were excluded and after making allowance for age, sex, and disease pattern. Of the subscales used only the functional status scales for bladder and visual function seemed to show benefit: this was not reflected in the visual analogue scales filled in by the patients and may have occurred by chance.
The target of recruiting 56 patients proved not to be possible in a reasonable time despite a large base population. The mean actual decline in EDSS of the 24 randomised patients in the study was 0-79 (SD 1-05) and a post hoc calculation of the power of the study to detect a difference of this order between treated and sham groups was 065.
Thus there is a possibility of 0.35 of a false negative result. Nevertheless we infer from the overall pattern of clinical results that it is unlikely that a major clinical benefit has been missed. In particular the changes on the functional scale, which was the main positive outcome feature in the United States study, show no trend in favour of the treatment group.
We categorised TLI treated patients into those with lymphocyte counts > or <850/mm' in the three months after the completion of treatment and into those improving or worsening by one full grade on the EDSS between pretreatment and six months and six to 12 months but found no evidence that those who deteriorated least had the lower lymphocyte counts. This contrasts with the finding that patients with counts <900/mm3 benefited more than those with higher counts in a group of 27 patients who received treatment (three openly).36 We (table 5) : on first testing the sham group took longer than the treated group, at one year the same time, and at two years was quicker to complete the task. The sham group also achieved significantly more correct categories. Previous studies have indicated the importance of speed of information processing in multiple sclerosis. '7 In this respect the treated group seemed to be more impaired than the sham treated group at two years of follow up. The samples (11/14 randomised TLI and 5/10 sham), however, are small and data acquisition was more complete in the treated group-a possible source of bias. The data emphasise the need for psychometric evaluation in future long term trials of this type.
Overall, side effects in the study were associated with active treatment but have not so far caused excess mortality. Amenorrhea was a significant although expected event that would limit the usefulness of this treatment were it to be of benefit: a recent study has emphasised the morbidity of ovarian failure after total body irradiation for leukaemia. '8 The increased risk of infection is both expected and relevant. In the United States study, currently there have been six deaths in 51 patients receiving TLI (12%) v three deaths in 21 patients receiving sham irradiation (14%) (SD Cook, personal communication). The original reported excess of deaths in their treatment group was associated with either advanced multiple sclerosis or increased susceptibility to and poorer progno-sis from infection.20 On average our patients were slightly less disabled than those in the United States study but our average follow up remains shorter than that of Cook et al where most deaths occurred between 42 and 54 months after therapy. 20 We would support the view that the prognosis of infection in a severely disabled patient with multiple sclerosis may be adversely affected by previous lymphoid irradiation. It is possible that avoidance of splenic-irradiation might reduce this risk without a reduction of efficacy in terms of depression of lymphocyte counts." 5 So far during follow up we have not encountered "iew malignant-disease (previous malignant disease excluded patients from entry). Evidence of the magnitude of this risk comes from long term follow up of patients with Hodgkin's disease treated with TLI and or chemotherapy. In a study of 2846 patients first treated from 1970-87 for Hodgkin's disease the relative risk of leukaemia appeared not to be appreciably increased by TLI alone whereas extensive radiotherapy was associated with a relative risk of 1 9 (95% CI 1 0 to 3. 1) for all solid tumours other than lung cancer and 3 9 (1.7 to 7 8) for lung cancer. 39 The dose in that study was typically greater (3500-4000 cGy) than in the present protocol. Nevertheless, even relatively low risks need to be considered carefully in administering such treatment to patients who may be young, who may receive at certain times other immunosuppressive regimes, and in whom the individual prognosis may be uncertain.
In conclusion we have effectively produced prolonged immunosuppression in a group of patients with progressive disability from multiple sclerosis. Although there is some evidence for a modest effect on the rate of accrual of brain lesions clear clinical benefit was not detectable. There are substantial practical and theoretical grounds for exercising great caution in the administration of TLI to patients with multiple sclerosis, not least being the increased risks of amenorrhea, infection, and long term incidence of solid tumour. In our view possible clinical benefits demonstrated in the United States study '9 together with slight radiological benefit in the present study, although of theoretical interest, are outweighed by the excess morbidity, possible mortality, and lack of reproducible efficacy and the technique cannot be recommended for routine clinical practice. TLI fits with a number of other non-specific immunosuppressive regimes in producing small or no clinical benefits at some inconvenience and risk to patients with multiple sclerosis.41 19 It is possible that TLI (perhaps without splenic irradiation) will be an effective method of inducing immunosuppression in multiple sclerosis, which might then be followed by longer term therapy with another immunosuppressive agent. Clinical trials of better targeted long term regimes, based on more detailed understanding of the mechanisms of the disease and monitored with frequent MRI3440 as well as clinical indices, still offer the surest way forward.
